Longer survival in patients with human papillomavirus-related head and neck cancer after positive postradiation planned neck dissection

Head and Neck

Volumn 37, Issue 7, 2015, Pages 946-952

  Huang, Shao Hui ^a   Patel, Samip ^b   O'Sullivan, Brian ^a   Shen, Xiaowei ^c   Xu, Wei ^c   Weinreb, Ilan ^c   Perez Ordonez, Bayardo ^c   Irish, Jonathan ^b   Waldron, John ^a   Gullane, Patrick ^b   Gilbert, Ralph ^b   Brown, Dale ^b   Kim, John ^a   Freeman, Jeremy ^b   De Almeida, John R ^b   Goldstein, David ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

head and neck cancer; human papillomavirus; planned neck dissection; radiotherapy; survival

Indexed keywords

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; HEAD AND NECK CANCER; HUMAN; MALE; NECK DISSECTION; OVERALL SURVIVAL; PRIORITY JOURNAL; SECOND CANCER; WART VIRUS; CARCINOMA, SQUAMOUS CELL; FOLLOW UP; HEAD AND NECK NEOPLASMS; ISOLATION AND PURIFICATION; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME; VERY ELDERLY; VIROLOGY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NECK DISSECTION; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84931395579     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23690     Document Type: Article

References (30)

1. Gillison ML, D'Souza G, Westra W, et al., Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 2008; 100: 407-420.
2. Halec G, Holzinger D, Schmitt M, et al., Biological evidence for a causal role of HPV16 in a small fraction of laryngeal squamous cell carcinoma. Br J Cancer 2013; 109: 172-183.
3. Wendt M, Romanitan M, Nasman A, et al., Presence of human papillomaviruses and p16 expression in hypopharyngeal cancer. Head Neck 2014; 36: 107-112.
4. Lingen MW, Xiao W, Schmitt A, et al., Low etiologic fraction for high-risk human papillomavirus in oral cavity squamous cell carcinomas. Oral Oncol 2013; 49: 1-8.
5. Ang KK, Harris J, Wheeler R, et al., Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363: 24-35.
6. O'Sullivan B, Huang SH, Siu LL, et al., Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. J Clin Oncol 2013; 31: 543-550.
7. Lango MN, Andrews GA, Ahmad S, et al., Postradiotherapy neck dissection for head and neck squamous cell carcinoma: pattern of pathologic residual carcinoma and prognosis. Head Neck 2009; 31: 328-337.
8. Ganly I, Bocker J, Carlson DL, et al., Viable tumor in postchemoradiation neck dissection specimens as an indicator of poor outcome. Head Neck 2011; 33: 1387-1393.
9. Trotti A, Gillison M,. Phase III trial of radiotherapy plus cetuximab versus chemoradiotherapy in HPV-associated oropharynx cancer. [NCT01302834], (ed June 9, 2011), RTOG, 2011.
10. Huang SH, O'Sullivan B, Weinreb I, et al., Patterns of failure and histopathologic outcome predictors following definitive radiotherapy and planned neck dissection with residual disease. Head Neck 2012; 34: 913-922.
11. Shonka DC Jr, Shoushtari AN, Thomas CY, et al., Predicting residual neck disease in patients with oropharyngeal squamous cell carcinoma treated with radiation therapy: utility of p16 status. Arch Otolaryngol Head Neck Surg 2009; 135: 1126-1132.
12. Simon C, Goepfert H, Rosenthal DI, et al., Presence of malignant tumor cells in persistent neck disease after radiotherapy for advanced squamous cell carcinoma of the oropharynx is associated with poor survival. Eur Arch Otorhinolaryngol 2006; 263: 313-318.
13. Sandulache VC, Ow TJ, Daram SP, et al., Residual nodal disease in patients with advanced-stage oropharyngeal squamous cell carcinoma treated with definitive radiation therapy and posttreatment neck dissection: association with locoregional recurrence, distant metastasis, and decreased survival. Head Neck 2013; 35: 1454-1460.
14. Stoehlmacher-Williams J, Villanueva C, Foa P, et al., Safety and efficacy of panitumumab (pmab) in HPV-positive (+) and HPV-negative (-) recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): analysis of the global phase III SPECTRUM trial. J Clin Oncol 2012; 30 (Suppl): abstract 5504.
15. Mehra R, Egloff AM, Li S, et al., Analysis of HPV and ERCC1 in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). J Clin Oncol 2013; 31 (Suppl): abstract 6006.
16. Vermorken JB, Stöhlmacher J, Oliner KS, et al., Safety and efficacy of panitumumab (pmab) in HPV positive (+) and HPV negative (-) recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): analysis of the phase III SPECTRUM trial. Eur J Cancer 2011; 47: 13.
17. Shi W, Kato H, Perez-Ordonez B, et al., Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma. J Clin Oncol 2009; 27: 6213-6221.
18. Mehanna H, Beech T, Nicholson T, et al., Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer-systematic review and meta-analysis of trends by time and region. Head Neck 2013; 35: 747-755.
19. Hobbs CG, Sterne JA, Bailey M, et al., Human papillomavirus and head and neck cancer: a systematic review and meta-analysis. Clin Otolaryngol 2006; 31: 259-266.
20. Huang SH, O'Sullivan B, Xu W, et al., Temporal nodal regression and regional control after primary radiation therapy for N2-N3 head-and-neck cancer stratified by HPV status. Int J Radiat Oncol Biol Phys 2013; 87: 1078-1085.
21. Waldron J, Warde P, Irish J, et al., A dose escalation study of hyperfractionated accelerated radiation delivered with integrated neck surgery (HARDWINS) for the management of advanced head and neck cancer. Radiother Oncol 2008; 87: 173-180.
22. Cox JD, Stetz J, Pajak TF,. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995; 31: 1341-1346.
23. Ezzati M, Lopez AD,. Estimates of global mortality attributable to smoking in 2000. Lancet 2003; 362: 847-852.
24. Chen AM, Chen LM, Vaughan A, et al., Tobacco smoking during radiation therapy for head-and-neck cancer is associated with unfavorable outcome. Int J Radiat Oncol Biol Phys 2011; 79: 414-419.
25. Huang SH, Perez-Ordonez B, Weinreb I, et al., Natural course of distant metastases following radiotherapy or chemoradiotherapy in HPV-related oropharyngeal cancer. Oral Oncol 2013; 49: 79-85.
26. Sinha P, Thorstad WT, Nussenbaum B, et al., Distant metastasis in p16-positive oropharyngeal squamous cell carcinoma: a critical analysis of patterns and outcomes. Oral Oncol 2014; 50: 45-51.
27. Wong K, Huang SH, O'Sullivan B, et al., Point-of-care outcome assessment in the cancer clinic: audit of data quality. Radiother Oncol 2010; 95: 339-343.
28. Robinson M, Sloan P, Shaw R,. Refining the diagnosis of oropharyngeal squamous cell carcinoma using human papillomavirus testing. Oral Oncol 2010; 46: 492-496.
29. El-Naggar AK, Westra WH,. p16 expression as a surrogate marker for HPV-related oropharyngeal carcinoma: a guide for interpretative relevance and consistency. Head Neck 2012; 34: 459-461.
30. Vent J, Haidle B, Wedemeyer I, et al., p16 Expression in carcinoma of unknown primary: diagnostic indicator and prognostic marker. Head Neck 2013; 35: 1521-1526.